Dr. Steven Quay Of Atossa Therapeutics Inc (NASDAQ: ATOS) Will Discuss Phase 2 Clinical Trial Data Of Endoxifen In Patients With Breast Cancer Before Surgery At A Webinar On June 9, 2021

Atossa Therapeutics Inc (NASDAQ: ATOS)’s CEO, Steven Quay, will discuss and release Phase 2 trial final data of Endoxifen examined in breast cancer patients before surgery at a webinar on June 9, 2021. Other key executives to attend this webinar are its VP (Clinical, CMC, and Regulatory) – B. Heather […]